DSM-Firmenich schedules Ridinger vote: DSM-Firmenich stock gains 1.31 percent

Published on 10/19/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue was EUR 4.66 billion after 5.00 percent organic growth. DSM-Firmenich stock costs EUR 108.45, 1.31 percent above its Xetra close.

Corporate dates and operating scale

Shareholders are due to vote on Richard Ridinger on October 19, 2026.
First-half revenue reached EUR 4.66 billion after 5.00 percent organic growth.
DSM-Firmenich stock trades at EUR 108.45 at 10:29 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.31 percent above the Xetra close of October 16, 2026.
The next trading update is scheduled for November 4, 2026.

Schwarzweiß-Reportagefoto eines Ingenieurs an großen Bioreaktoren — dsm-firmenich AG (ISIN CH1216478797) fertigt Vitamine und Enzyme in industriellen Bioreaktoren, dokumentarisch schwarzweiß fotografiert, Illustration mit AI erstellt.

DSM-Firmenich is due to hold a shareholder vote on Richard Ridinger's proposed appointment as board chair on October 19, 2026, while the stock trades 1.31 percent above the Xetra close. Finanztrends reported the proposed vote and also described new operating initiatives dated October 6, 2026.

Buyback reduces the share count

The company completed its EUR 540.00 million repurchase program on October 1, 2026, according to dsm-firmenich. The program repurchased 7,169,147 shares, including 6,488,446 shares intended for cancellation. The company said the cancellation should reduce issued shares by 2.60 percent, from 253,626,947 to 247,138,501 shares by the end of the first quarter of 2027.

The operating picture remains tied to cash conversion. In the first half of 2026, revenue from continuing operations reached EUR 4.66 billion after 5.00 percent organic growth, while adjusted EBITDA was EUR 900.00 million and the margin was 19.30 percent, as reported by De Belegger on October 3, 2026. Management maintained a 2026 target of about 20.00 percent adjusted EBITDA margin and 11.00 percent to 12.00 percent adjusted gross operating free cash flow as a share of revenue.

What comes next for shareholders

The chronology is clear: the company reported first-half revenue of EUR 4.66 billion on July 30, 2026, completed the EUR 540.00 million buyback on October 1, 2026, and scheduled the October 19, 2026 vote on Richard Ridinger. The first event supplied the operating baseline, the second changes the share count, and the third is the immediate governance date.

Two dates shape the calendar

The shareholder vote is scheduled for October 19, 2026, and the next trading update is scheduled for November 4, 2026. The latter date was identified in the recent company-focused review by De Belegger.

Stock trades above the Xetra close

The reference price gives the market context: DSM-Firmenich was trading at EUR 108.45 at Lang & Schwarz on October 19, 2026, at 10:29 a.m. CEST, up EUR 1.40 or 1.31 percent versus the Xetra close of October 16, 2026 at EUR 107.05. The 52-week range was EUR 55.22 to EUR 108.55 as of October 16, 2026.

The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.